Ann: Results of LCT Parkinsons trial require further analysis, page-80

Followed LCT for sometime now.
Made some money, lost some money. That's spec Biotech.

The reality now is...
yes the sample size may have been too small to accurately measure true statistics. But its not these guys first rodeo. The trial had been well planned and managed.
There may still be some long term benefits at 52 and 78 week mark, however will investors hang in there for that amount of time when there is already writing on the wall?
With only $6m or so in the bank and a cash burn of $1m+ a quarter without ramping up new R&D it wont be long before the company needs more capital.

Whats the EV of the company now with no lead candidate?
$5m< cash, pigs? (maybe worthless), IP of IMMUPEL (a few other immune capsules out there)? DIABCELL (seems Diatranz Otsuka has buried that one, previous results not overly impressive)
$20million is probably about right, if not generous.

Its a bitter day to swallow